Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | SDCBP | O00560 | 1/20 | 0.45 |
| ▸ | SDC2 | P34741 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180689 | 0.87 | L3MBTL1 (0.61) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL435901 | 0.86 | GLS (0.54) | L3MBTL1NAMPTHDAC1CA1KDM4A | |
| SCHEMBL506202 | 0.81 | GAA (0.57) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL5796279 | 0.81 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL8372079 | 0.81 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL1164796 | 0.81 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL15259134 | 0.81 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL12685839 | 0.81 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL2567630 | 0.80 | HDAC1 (0.57) | L3MBTL1NAMPTGAAHDAC1CA1 | |
| SCHEMBL1691047 | 0.80 | HDAC1 (0.67) | L3MBTL1NAMPTGAAHDAC1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | BROUGH STEPHEN (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| US-8163905-B2 | Compounds and their uses 708 | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | CYP3A7, CYP2C8, CYP2C18 | L3MBTL1 4827/4885NAMPT 706/4885GAA 1308/4885 |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 | L3MBTL1 3952/4885NAMPT 1719/4885GAA 1796/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | L3MBTL1 4427/4885NAMPT 1158/4885GAA 3504/4885 |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | CYP3A7, CYP3A5, CYP2C19 | L3MBTL1 4142/4885NAMPT 1394/4885GAA 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.